Blackston Financial Advisory Group LLC Has $537,000 Stock Holdings in AbbVie Inc. $ABBV

Blackston Financial Advisory Group LLC lowered its position in shares of AbbVie Inc. (NYSE:ABBV) by 55.4% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,317 shares of the company’s stock after selling 2,876 shares during the period. Blackston Financial Advisory Group LLC’s holdings in AbbVie were worth $537,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ABBV. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie in the second quarter valued at approximately $26,000. Caitlin John LLC acquired a new stake in AbbVie during the 3rd quarter worth approximately $33,000. Financial Gravity Companies Inc. bought a new stake in AbbVie during the 2nd quarter worth approximately $36,000. Delos Wealth Advisors LLC bought a new stake in AbbVie during the 2nd quarter worth approximately $39,000. Finally, Redmont Wealth Advisors LLC acquired a new position in AbbVie in the 3rd quarter valued at approximately $41,000. 70.23% of the stock is currently owned by institutional investors.

Insider Activity

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.25% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Berenberg Bank set a $275.00 price target on shares of AbbVie in a report on Tuesday, January 20th. Citigroup lowered their target price on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. BMO Capital Markets reaffirmed an “outperform” rating and set a $258.00 target price on shares of AbbVie in a report on Thursday, January 15th. Evercore reduced their price target on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. Finally, Piper Sandler increased their price target on AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $253.15.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat and raised FY/Q1 outlook — AbbVie posted better‑than‑expected Q4 EPS and revenue and gave FY‑2026 guidance (14.37–14.57 EPS), supporting the bull case for continued top‑line and EPS growth. AbbVie (ABBV): Buy, sell, or hold post Q4 earnings?
• Positive Sentiment: Pipeline catalysts: neuroscience momentum and new approvals could drive revenue — the neuroscience unit generated ~$10.8B in 2025 and analysts see upside to ~$12.5B in 2026 as Vyalev ramps and tavapadon awaits FDA review. Will AbbVie’s Neuroscience Segment Continue to Aid Top Line in 2026?
• Positive Sentiment: Positive Phase‑3 SKYRIZI Crohn’s data strengthens the immunology franchise and expands commercial potential for risankizumab. This data is a material upside to long‑term revenue expectations for immunology products. Did Positive Phase 3 SKYRIZI Crohn’s Data Just Shift AbbVie’s (ABBV) Immunology Investment Narrative?
• Neutral Sentiment: Analyst/market attention: some bullish writeups call ABBV a core, buy‑and‑hold dividend name and note the stock has rallied since earnings — supportive for sentiment but already reflected in recent gains. AbbVie: The only big pharma stock I’d consider a buy-and-never-sell
• Neutral Sentiment: Operational investment: AbbVie will spend $380M to expand its North Chicago campus — a long‑term capacity/R&D bet that supports future growth but increases near‑term capex. AbbVie to invest $380 million in North Chicago campus to make next generation medicines
• Negative Sentiment: Debt issuance: AbbVie completed an $8B senior notes offering, which increases leverage and raises capital‑structure risk that investors may price in, especially given the company’s already elevated payout metrics. AbbVie Completes $8 Billion Senior Notes Financing Offering
• Negative Sentiment: Dividend and leverage concerns: analysts caution that a very high payout ratio and significant debt levels warrant caution for income investors despite strong free cash flow. That raises risk of multiple compression if growth slows. Dividend Stock Analysis – Abbvie Inc.
• Negative Sentiment: Near‑term price pressure: recent sessions show ABBV underperforming the wider market on profit‑taking and macro moves, which can amplify volatility after the post‑earnings run. AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights

AbbVie Trading Down 0.8%

Shares of ABBV stock opened at $230.41 on Friday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The firm has a market capitalization of $407.40 billion, a PE ratio of 97.63, a price-to-earnings-growth ratio of 0.81 and a beta of 0.34. The firm has a fifty day simple moving average of $224.72 and a two-hundred day simple moving average of $223.97.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. AbbVie’s dividend payout ratio is presently 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.